The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a strategic pivot toward diversified consumer goods, Tilray Brands' latest results signal a successful transition beyond its core cannabis roots. According to reports, the company achieved record net revenue of $915 million for the 2026 fiscal year. This performance was bolstered by a 34% increase in international medical cannabis revenue, which strengthened the company's footprint across European markets and expanded patient access.
The record results were driven by strategic expansion, including the BrewDog acquisition which ignited the global growth of Tilray’s beverage platform. Alongside revenue growth, the company significantly reduced its net debt to $0.7 million, strengthening its balance sheet according to analyst data. Looking ahead, the company issued positive guidance for fiscal year 2027, forecasting adjusted EBITDA between $68 million and $75 million, representing continued operational momentum.
In the markets, TLRY was priced at $4.03 at close July 27, 2026, having traded between a day low of $3.91 and a high of $4.08. With no major upcoming catalysts listed in the immediate economic calendar, investors will focus on the company's ability to execute its beverage expansion strategy and meet its ambitious double-digit growth targets for the 2027 fiscal year.